Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVM NASDAQ:ATRA NASDAQ:CLLS NASDAQ:INBX NASDAQ:KRYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$4.36$4.30$1.78▼$5.75$96.26M0.87452,470 shsN/AATRAAtara Biotherapeutics$9.24-1.8%$5.92$3.92▼$19.15$83.25M-0.31.18 million shs15,224 shsCLLSCellectis$3.82+5.2%$3.70$1.33▼$5.48$383.30M2.9440,427 shs1,918 shsINBXInhibrx Biosciences$106.54-2.7%$89.15$12.24▼$155.29$1.56B3.88318,528 shs89,750 shsKRYSKrystal Biotech$298.56+1.8%$269.52$122.80▼$319.48$8.78B0.5297,739 shs51,497 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies0.00%0.00%0.00%0.00%+97.29%ATRAAtara Biotherapeutics+2.84%-4.08%+78.56%+112.42%+39.82%CLLSCellectis-5.71%-8.33%-17.87%-10.59%+134.19%INBXInhibrx Biosciences+3.51%+0.79%+24.12%+34.24%+778.19%KRYSKrystal Biotech+0.53%-5.48%+6.96%+3.53%+121.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$4.36$4.30$1.78▼$5.75$96.26M0.87452,470 shsN/AATRAAtara Biotherapeutics$9.24-1.8%$5.92$3.92▼$19.15$83.25M-0.31.18 million shs15,224 shsCLLSCellectis$3.82+5.2%$3.70$1.33▼$5.48$383.30M2.9440,427 shs1,918 shsINBXInhibrx Biosciences$106.54-2.7%$89.15$12.24▼$155.29$1.56B3.88318,528 shs89,750 shsKRYSKrystal Biotech$298.56+1.8%$269.52$122.80▼$319.48$8.78B0.5297,739 shs51,497 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies0.00%0.00%0.00%0.00%+97.29%ATRAAtara Biotherapeutics+2.84%-4.08%+78.56%+112.42%+39.82%CLLSCellectis-5.71%-8.33%-17.87%-10.59%+134.19%INBXInhibrx Biosciences+3.51%+0.79%+24.12%+34.24%+778.19%KRYSKrystal Biotech+0.53%-5.48%+6.96%+3.53%+121.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.00Hold$10.50140.83% UpsideATRAAtara Biotherapeutics 2.00Hold$9.502.81% UpsideCLLSCellectis 2.83Moderate Buy$6.7576.70% UpsideINBXInhibrx Biosciences 2.33Hold$150.0040.79% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.118.56% UpsideCurrent Analyst Ratings BreakdownLatest KRYS, CLLS, INBX, ATRA, and ADVM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026ATRAAtara Biotherapeutics Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/18/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.005/8/2026ATRAAtara Biotherapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold ➝ Buy$6.00 ➝ $13.005/8/2026ATRAAtara Biotherapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$13.005/5/2026KRYSKrystal Biotech EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$300.005/5/2026KRYSKrystal Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$371.00 ➝ $378.005/4/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.004/24/2026INBXInhibrx Biosciences Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/20/2026CLLSCellectis Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/14/2026CLLSCellectis Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$8.004/9/2026KRYSKrystal Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)(Data available from 5/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum BiotechnologiesN/AN/AN/AN/A$3.40 per shareN/AATRAAtara Biotherapeutics$120.77M0.69$4.91 per share1.88($4.14) per share-2.23CLLSCellectis$68.07M5.63N/AN/A$0.60 per share6.37INBXInhibrx Biosciences$1.30M1,202.26N/AN/A($1.43) per share-74.50KRYSKrystal Biotech$417.30M21.09$7.46 per share40.02$43.31 per share6.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$130.93M-$8.58N/AN/AN/AN/A-3,476.17%-152.07%N/AATRAAtara Biotherapeutics$32.69M-$0.67N/A46.20N/A-40.91%-79.12%-35.29%5/21/2026 (Estimated)CLLSCellectis-$67.59M-$0.67N/AN/AN/A-89.51%-80.66%-20.51%7/30/2026 (Estimated)INBXInhibrx Biosciences-$140.05M-$8.39N/AN/AN/AN/A-563.90%-72.32%N/AKRYSKrystal Biotech$204.83M$7.4839.8028.38N/A53.92%19.25%17.62%8/3/2026 (Estimated)Latest KRYS, CLLS, INBX, ATRA, and ADVM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026ATRAAtara Biotherapeutics-$0.3295N/AN/AN/A$2.90 millionN/A5/14/2026Q1 2026INBXInhibrx Biosciences-$1.6750-$2.15-$0.4750-$2.15N/AN/A5/12/2026Q1 2026ATRAAtara Biotherapeutics-$0.3295-$0.29+$0.0395-$0.29$2.90 million$0.52 million5/11/2026Q1 2026CLLSCellectis-$0.2583-$0.18+$0.0783-$0.18$11.04 million$7.55 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 million3/19/2026Q4 2025CLLSCellectis-$0.10-$0.26-$0.16-$0.26$10.74 million$15.50 million3/19/2026Q4 2025INBXInhibrx Biosciences-$2.08-$2.11-$0.03-$2.11N/AN/A3/16/2026Q4 2025ATRAAtara Biotherapeutics-$0.68-$0.25+$0.43-$0.36$0.70 million$1.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A0.650.65ATRAAtara BiotherapeuticsN/A2.162.16CLLSCellectis1.131.521.52INBXInhibrx Biosciences12.586.466.46KRYSKrystal BiotechN/A9.469.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%ATRAAtara Biotherapeutics70.90%CLLSCellectis63.90%INBXInhibrx Biosciences82.46%KRYSKrystal Biotech86.29%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies6.00%ATRAAtara Biotherapeutics41.20%CLLSCellectis16.41%INBXInhibrx BiosciencesN/AKRYSKrystal Biotech13.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19022.08 million20.75 millionOptionableATRAAtara Biotherapeutics3309.01 million5.30 millionNo DataCLLSCellectis290100.34 million83.87 millionOptionableINBXInhibrx Biosciences16614.67 millionN/AOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableKRYS, CLLS, INBX, ATRA, and ADVM HeadlinesRecent News About These CompaniesTimesSquare Capital Management LLC Cuts Position in Krystal Biotech, Inc. $KRYS4 hours ago | marketbeat.comAtle Fund Management AB Sells 8,338 Shares of Krystal Biotech, Inc. $KRYSMay 20 at 3:10 AM | marketbeat.comPittsburgh Biotech's Gene Gel Wins UK Green Light for DEB WoundsMay 19 at 1:10 PM | hoodline.comHKrystal Biotech gains regulatory approval to sell gene therapy in the United KingdomMay 19 at 1:10 PM | bizjournals.comKrystal Biotech's (KRYS) Buy Rating Reaffirmed at HC WainwrightMay 18 at 8:15 AM | marketbeat.comKrystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis BullosaMay 18 at 8:00 AM | globenewswire.comVIRGINIA RETIREMENT SYSTEMS ET Al Grows Stock Holdings in Krystal Biotech, Inc. $KRYSMay 16, 2026 | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 16, 2026 | americanbankingnews.comKrystal Biotech, Inc. (NASDAQ:KRYS) Given Average Recommendation of "Moderate Buy" by AnalystsMay 16, 2026 | marketbeat.comKrystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comThis Profitable Biotech Stealthily Climbs Into A Buy ZoneMay 11, 2026 | investors.comKrystal Biotech (KRYS) Is Up 6.5% After Vyjuvek-Fueled Q1 Profit Jump And Investor Conference UpdateMay 11, 2026 | finance.yahoo.comKrystal Biotech (NASDAQ:KRYS) Hits New 52-Week High - Here's WhyMay 11, 2026 | marketbeat.comState of New Jersey Common Pension Fund D Reduces Stock Position in Krystal Biotech, Inc. $KRYSMay 11, 2026 | marketbeat.comKrystal Biotech: Vyjuvek Is Not The Primary AssetMay 10, 2026 | seekingalpha.comKrystal Biotech, Inc. $KRYS Shares Purchased by Principal Financial Group Inc.May 10, 2026 | marketbeat.comKrystal Biotech (NASDAQ:KRYS) Rating Increased to Buy at Wall Street ZenMay 9, 2026 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Krystal Biotech (KRYS), Twist Bioscience (TWST)May 8, 2026 | theglobeandmail.comGuggenheim Sticks to Their Buy Rating for Krystal Biotech (KRYS)May 8, 2026 | theglobeandmail.comKrystal Biotech to Present at BofA Securities 2026 Health Care ConferenceMay 7, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Encompass Health (EHC)May 7, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026Datadog Soars, Dynatrace Slumps: Gap Widens in AI Agent StocksBy Leo Miller | May 18, 2026KRYS, CLLS, INBX, ATRA, and ADVM Company DescriptionsAdverum Biotechnologies NASDAQ:ADVMAdverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Atara Biotherapeutics NASDAQ:ATRA$9.24 -0.17 (-1.81%) As of 11:15 AM EasternAtara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Cellectis NASDAQ:CLLS$3.82 +0.19 (+5.23%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Inhibrx Biosciences NASDAQ:INBX$106.54 -2.97 (-2.71%) As of 11:34 AM Eastern This is a fair market value price provided by Massive. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Krystal Biotech NASDAQ:KRYS$298.56 +5.26 (+1.79%) As of 11:35 AM Eastern This is a fair market value price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Vertical Aerospace: Pre-Flight Checks Point to a Breakout HIVE Weaponizes Power for an AI Pivot Strategy Inc. Buys Bitcoin and Eyes a Dividend Amid Market Fear Arhaus Stock Drops to 52-Week Low After Q1 Earnings Tesla Ends Model S and X Era, Bets Everything on What's Next Why Home Depot’s Sell-Off Could Become a Huge Opportunity Palo Alto Networks Up 70%: Can the Rally Last Into June? Brady Corp Wires Up a Massive AI-Powered Breakout Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
